Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + omeprazole
- Development stage
- Unknown
- Lead developer
- Boots
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ibuprofen + omeprazole is a combination of two drugs: ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), and omeprazole, a proton pump inhibitor (PPI). This combination is not available as a fixed-dose product but may be used together in clinical practice to manage pain or inflammation while reducing the risk of NSAID-induced gastrointestinal adverse effects. Ibuprofen works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby decreasing prostaglandin synthesis involved in pain, fever, and inflammation. Omeprazole suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. The co-administration aims to provide effective analgesia while protecting against NSAID-associated GI complications such as ulcers[3][1][7].
- Brand names
- (no known fixed-dose combination brand names for ibuprofen + omeprazole)
- Other names
- ibuprofen + omeprazole
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on ibuprofen + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + omeprazole.